47 results about "Lymphocytic cell" patented technology

A conjugate contains an amatoxin, a target-binding moiety wherein the target is CD37, i.e., a CD37-binding moiety, and optionally a linker linking the amatoxin and said CD37-binding moiety, and the conjugate is prepared in a synthesis method. A pharmaceutical composition contains the conjugate for use in the treatment of immune cell-, particularly B-cell and / or lymphoma associated diseases and / or malignancies.

The invention provides a construction method and a construction system of a chronic lymphocytic leukemia prediction model based on machine learning, electronic equipment and a storage medium, and relates to the field of chronic lymphocytic leukemia prognosis research. The construction method comprises the steps of obtaining original sample data, and performing preliminary screening; performing data cleaning on the screened sample data; determining a prediction factor from the plurality of features of the cleaned sample data; dividing the cleaned sample data corresponding to the prediction factor and the target variable into a training set and a test set; inputting the training set after unbalance processing into a LightGBM model for training to obtain a prediction model; inputting the test set into a prediction model, performing hyper-parameter optimization on the prediction model, and evaluating the performance of the prediction model; calibrating the prediction model to obtain a calibrated prediction model; the method has the beneficial effects that the method can be realized only by depending on conventionally available predictive factors, and the patient screening can be realized before the CLL clinical symptoms appear.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

This invention relates to the application of PGG in the preparation of drugs for treating acute leukemia, belonging to the field of biomedical technology. To address the problems of narrow application range and easy development of drug resistance in existing acute leukemia treatments, this invention provides the application of PGG in the preparation of drugs for treating acute leukemia. Experiments have shown that PGG can inhibit the viability, proliferation, and colony formation of human acute myeloid leukemia cells (MOLM-13) and human acute lymphoblastic leukemia cells (Jurkat), and induce their apoptosis. In animal models, intraperitoneal injection of PGG can prolong the survival days of mice with acute leukemia and reduce the infiltration of leukemia cells in the liver, spleen, and bone marrow tissues. In this invention, PGG directly inhibits the viability of acute leukemia cells and can simultaneously inhibit AML and ALL, without relying on specific gene mutations, resulting in a lower risk of drug resistance, more flexible clinical use, and broader patient coverage, showing promising clinical application prospects.

Epigenetically modified DNA targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, are provided that bind to or target one or more target sites in the IL-2 gene or its regulatory elements in cells such as lymphoid cells (e.g., T cells). In some embodiments, the provided epigenetically modified DNA targeting systems modulate the phenotype or activity of lymphoid cells, or the function of lymphoid cells such as the phenotype or activity of T cells. In some embodiments, methods and uses relating to the provided compositions in the modulation of lymphoid cells such as T cells are also provided, for example, in connection with adoptive T cell therapy.

Discussed herein are pharmaceutical compositions containing Ibrutinib and processes for preparing them. The compositions may be utilized in the treatment of a variety of conditions including, without limitation, B-cell proliferative disorders such as non-Hodgkin lymphoma (diffuse large B cell lymphoma, follicular lymphoma, mantle cell lymphoma or burkitt lymphoma), Waldenstrom macroglobulinemia, plasma cell myeloma, chronic lymphocytic leukemia, lymphoma, or leukemia. These compositions are designed for oral ingestion. The compositions are contained within a capsule such as a standard or sprinkle or in a liquid formulation such as a suspension. In one embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, and magnesium stearate. In another embodiment, the pharmaceutical composition contains Ibrutinib, a salt, prodrug, or metabolite thereof, microcrystalline cellulose, carboxymethylcellulose sodium, hydroxypropylmethylcellulose, citric acid monohydrate, disodium hydrogen phosphate, sucralose, sodium methyl parahydroxybenzoate, sodium ethyl parahydroxybenzoate, concentrated hydrochloric acid, sodium hydroxide, and water.

The present disclosure relates to CD19 / 22 CAR T-cell products and methods for treating high risk or relapsed CD19+ or CD22+ haematological malignancies.

The present invention relates to the field of cell therapy, and specifically relates to a method for preparing a CAR-expressing T cell and a use. Disclosed in the present invention is a method for preparing a CAR-T cell, comprising the following steps: S1, collecting a T cell-containing cell population of an autologous or allogeneic donor of a subject; S2, administering lymphodepletion therapy to the subject for pretreatment; and S3, administering the T cell-containing cell population and a viral vector to the subject.

The invention belongs to the technical field of virus infection cell lines, and particularly relates to a rats kidney cell line and application thereof. Wherein the preservation number of the kidney cell line of the rats with the yellow chest is CCTCC (China Center For Type Culture Collection) NO: C2025271. The rats kidney cell line (RtK-15W) provided by the invention has multiple advantages of high sensitivity, high replication efficiency, quantitative detection, passage stability and the like on arenavirus; a reliable cell tool and an efficient, reliable and generalizable experimental platform are provided for separation and identification, in-vitro amplification, titer determination, pathogenesis research, drug screening, antibody neutralization experiment, vaccine effect evaluation and the like of arenaviruses (including lymphocytic choriomeningitis virus (LCMV) and Wenzhou virus (WENV)).

The invention belongs to the technical field of blood disease diagnosis, and provides a noninvasive screening method for acute B lymphocytic leukemia (B-ALL) based on a peripheral blood CD3 + CD19 + double positive cell subset, which comprises the following steps: detecting the proportion of CD3 + CD19 + double positive cells in peripheral blood through flow cytometry, and comparing the proportion with a proportion threshold in a positive judgment standard for judgment; when the detection result is greater than or equal to 0.20%, judging that the sample is positive; cD3 + CD19 + double positive cells exist in B-ALL peripheral blood, the detection rate of B-ALL peripheral blood in peripheral blood of healthy people and other types of leukemia patients is extremely low, and the B-ALL has high specificity; compared with bone marrow puncture and other invasive diagnosis methods, the non-invasive primary screening of B-ALL is realized, and the problem of insufficient specificity of the existing non-invasive detection technology is overcome; the kit is suitable for early screening of children B-ALL, dynamic monitoring of chemotherapy curative effect and prognosis evaluation, and has important clinical application value.

The present invention relates to a first composition comprising one of CD4+ T cells and CD8+ T cells for use with a second composition comprising the other of CD4+ T cells and CD8+ T cells in a method for treating a subject having chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), wherein the method comprises administering to the subject a dose of modified T cells comprising CD4+ and CD8+ T cells comprising a chimeric antigen receptor (CAR) that binds specifically to CD19, wherein: (i) the subject has relapsed following remission after treatment with, has become refractory to or has failed treatment with and / or has been intolerant to ibrutinib and venetoclax;(ii) administration comprises administering a plurality of separate compositions, wherein the plurality of separate compositions comprises the first composition comprising one of the CD4+ T cells and CD8+ T cells and the second composition comprising the other of the CD4+ T cells and CD8+ T cells, and (iii) the modified T cell dose comprises a defined ratio of CAR-expressing CD4+ cells to CAR-expressing CD8+ cells, optionally wherein the ratio is between approximately 1:3 and approximately 3:1;

The invention discloses application of prostaglandin PGE1 or PGE2 in preparation of a product for promoting proliferation of depleted precursor T cells. Specifically, prostaglandin PGE1 or PGE2 is added into a culture system of the T cells for culture, so that the efficiently amplified depleted precursor T cells can be obtained, meanwhile, the depletion degree of the CD8 + T cells can be inhibited, and when the prostaglandin PGE1 or PGE2 is stopped, the depleted precursor T cells can be rapidly and directionally differentiated into the CD8 + T cells. Therefore, when the prostaglandin PGE1 or PGE2 is applied to the in-vitro preparation process of adoptive T cell therapy, the total amount of CD8 + T cells can be remarkably increased, the proportion of Tpex is increased, the expression of a depletion marker is reduced, and a technical support is provided for clinical popularization of solid tumor infiltration lymphocyte therapy.

This invention discloses a method for obtaining high-purity NK cells using apheresis, belonging to the field of cell culture. The method includes the following steps: (1) obtaining peripheral blood mononuclear cells using the apheresis blood component method; (2) adding NK cell sorting reagent to the peripheral blood mononuclear cells, mixing evenly, and allowing to stand at room temperature to obtain a cell mixture; then adding the cell mixture to the upper layer of lymphocyte separation medium, centrifuging, removing the white membrane layer and above the transparent plasma, washing the harvested cell fluid to obtain enriched NK cells; (3) purifying using CD56 positively selected magnetic beads to obtain purified NK cells; (4) inoculating the purified NK cells into a culture container coated with CD16 antibody and allowing to stand. This method can obtain NK cells with a purity of over 99%, and the cells can expand hundreds of times after 17 days of in vitro culture, exhibiting strong anti-tumor function at low target ratios.

A preparation method of a particle hydrogel includes: mixing a gelatin nanoparticle, a calcium carbonate nanoparticle, an iron oxide nanoparticle, and a sodium alginate solution under alkaline conditions, and adding GDL to produce the particle hydrogel with improved mechanical properties, which is abbreviated as Ca-Alg / MCG. The present disclosure endows the hydrogel system with properties such as catheter injectability, vascular deliverability, and intravascular hardenability. The particle hydrogel can be delivered to fine blood vessels of tumors. The mechanical properties of the particle hydrogel can be gradually enhanced over time, which further improves the embolization efficacy of the particle hydrogel in blood vessels. Magnetic nanoparticles endow the particle hydrogel with magnetothermal responsiveness. Thus, the particle hydrogel can undergo a rapid temperature rise under an alternating magnetic field to further kill tumor cells. The particle hydrogel demonstrates improved embolization efficacy in rabbit renal embolization models and rabbit liver cancer-embolization models.

Provided are DNA-targeting systems, such as CRISPR-Cas / guide RNA (gRNA) systems, that bind to or target a target site in a DLL4 gene or a VCAM1 gene. In some embodiments, the provided DNA-targeting systems promote transcriptional activation of such genes to promote differentiation of hematopoietic progenitor cells into a differentiated population of cells, such as lymphoid progenitor or lymphoid cells. Also provided herein are methods and uses related to the provided compositions, for example in facilitating lymphoid progenitor cell differentiation.

According to an aspect of the present disclosure, an in vitro method of determining a genotype relating to canine atopic dermatitis (CAD) in a canine mammal may be provided. The method may comprise determining a presence or absence of a splice variant in a signaling lymphocytic activation molecule 1 (SLAMF1) gene of the canine mammal. The presence of the splice variant may indicate that the canine mammal is at increased risk of suffering from CAD and of passing the splice variant to its progeny.

The invention discloses a drug combination composition for resisting acute T lymphocytic leukemia and application, the drug combination composition for resisting acute T lymphocytic leukemia comprises an MCL1 inhibitor and afatinib, and the MCL1 inhibitor is S63845. The anti-acute T lymphocytic leukemia drug combination composition is applied to anti-tumor treatment. According to the present invention, the MCL1 inhibitor and the afatinib are combined, such that the significant apoptosis and pyroptosis can be induced, the MYC expression can be significantly reduced, and the purposes of T-ALL tumor cell killing and T-ALL treatment can be achieved.

This invention discloses the application of Huanglian Shangqing tablets combined with glucocorticoids in the preparation of drugs for treating leukemia. The Huanglian Shangqing tablets combined with glucocorticoids can inhibit the activity of Jurkat cells in a concentration-dependent manner; inhibit the proliferation of Jurkat cells in a concentration- and time-dependent manner; and significantly induce apoptosis in the human acute lymphoblastic leukemia cell line Jurkat. In animal experiments, compared with the model group, the Huanglian Shangqing tablets combined with glucocorticoids can increase the hematocrit ratio of leukemia mice, reduce the spleen burden in mice, have no obvious toxic side effects, and improve the survival rate of leukemia mice. Therefore, the Huanglian Shangqing tablets combined with glucocorticoids have the potential value of developing drugs to reverse glucocorticoid resistance in leukemia. Furthermore, Huanglian Shangqing tablets are already used clinically, which can effectively shorten the preclinical research period and has a very good application prospect.

The application provides a use of vincristine and lithium carbonate as co-active ingredients in the preparation of a medicament for treating tumors. The vincristine and lithium carbonate as co-active ingredients of the application have a killing effect on various leukemia cells, including human acute lymphoblastic leukemia cell lines, chronic myeloid leukemia cells, acute monocytic leukemia cell lines; in particular, for human acute lymphoblastic leukemia cell lines, compared with single free drugs (lithium carbonate or vincristine), lithium carbonate and vincristine free drug combination, the leukemia cell proliferation can be more effectively inhibited; in addition, the vincristine and lithium carbonate as co-active ingredients of the application can obviously stimulate the generation of granulocyte colony-stimulating factor, and alleviate the neutropenia side effect caused by chemotherapy.

Described are RNAi agents, compositions that include RNAi agents, and methods for inhibition of a thymic stromal lymphopoietin (TSLP) gene. The TSLP RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of an TSLP gene. Pharmaceutical compositions that include one or more TSLP RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described TSLP RNAi agents to pulmonary cells, in vivo, provides for inhibition of TSLP gene expression, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including pulmonary inflammation diseases such as asthma, including allergic asthma.

This invention relates to a group of antisense oligonucleotides that specifically inhibit thymic stromal lymphopoietin and their applications. The antisense oligonucleotide molecules are 16-20 bases in length. This invention also relates to the following applications of the antisense oligonucleotide molecules (ASO): (1) preparing preparations that inhibit the expression of thymic stromal lymphopoietin; (2) treating asthma, atopic dermatitis, COPD, sinusitis and nasal polyps.

This invention belongs to the field of food raw material science and discloses a chitosan-dextran nanopolysaccharide complex, its preparation method, and its applications. This invention proposes the use of an emulsifier. The combination of a low-concentration alkali and the emulsifier, along with a shortened processing time, preserves the natural properties of the complex while maximally removing related compounds such as proteins, lipids, fats, pigments, alkali-soluble dextran, and mineral compounds. This improves product purity while reducing CGC degradation during preparation and increasing removal efficiency. The chitosan-dextran nanopolysaccharide complex of this invention, due to its nano-sizing, provides optimal dispersibility in a hydrophilic environment, promoting better entry into the human body and interaction with cell surface receptors. It regulates the content of giant cells and the activity of T lymphocytes in vivo, effectively improving human immune regulation, and primarily inhibits tumors by enhancing the body's non-specific immune function.

The invention belongs to the field of molecular therapy, and particularly relates to a small-molecule inhibitor SUN-BTK02 of BTK protein and application of the small-molecule inhibitor SUN-BTK02 in inhibition of human B lymphoma cell proliferation. The invention aims to provide a small-molecule inhibitor SUN-BTK02 for BTK and application of the small-molecule inhibitor SUN-BTK02, and the inhibitor has an obvious inhibition effect on BTK and has a certain effect on treatment of B cell malignant tumors.

The present disclosure relates to a method of improving cognitive function in a subject. The method includes implanting group-2 innate lymphoid cells (ILC2) in a cranium of a subject, where the ILC2 was treated with an ILC2 activator. The present disclosure further relates to a method including selecting a subject having aging-associated cognitive decline and administering to the subject an activator of innate lymphoid cell activity under conditions effective to promote innate lymphoid cell activity. The present disclosure further relates to a method of improving cognition in a subject. The method includes selecting a subject having aging-associated cognitive decline and administering to the subject a cytokine selected from the group consisting of IL-33, IL-5, IL-7, IL-25, and thymic stromal lymphopoietin.

The present application provides an antibody molecule binding to human thymic stromal lymphopoietin (TSLP) and antigen-binding fragments thereof, and use of the antibody molecule or antigen-binding fragments thereof for preventing or treating TSLP high expression related purposes. The antibody molecule and antigen-binding fragments thereof of the present application can bind to human TSLP with high affinity, block the interaction between TSLP and its receptor, and significantly inhibit the secretion of chemokines such as CCL17, OPG, and dendritic cells, and can be used for treating diseases and disorders related to TSLP signaling and / or TSLP cell expression, such as inflammatory diseases or tumors.

This invention relates to a viral particle comprising a mutated lymphocytic choriomeningovirus (LCMV) glycoprotein (GP) and / or nucleic acid encoding said GP, wherein said viral particle has an enhanced ability to enter tumor cells. The invention also relates to said mutated GP, nucleic acid molecule encoding said GP, host cell containing cDNA of said nucleic acid molecule or the genome of said viral particle, method of producing said viral particle, and medical uses.

A novel, alternative, low-cost synthesis process for the in vitro production of carminic acid by using the hemolymph cells of the insect Dactylopius coccus Costa (cochineal scale insect) for use in the dye industry for food, cosmetics, pharmaceuticals and textiles.

According to the method for separating the CD34 < + > hematopoietic stem cells from the umbilical cord blood, the nonspecific clearance rate of the CD34 < + > cells is reduced by reducing the dosage of a RosetteSep antibody; the ratio of the RosetteSep antibody to the CD34 positive antibody to the magnetic beads is optimized; the albuginea layer containing CD34 + cells and a part of density gradient centrifugate below the albuginea layer are absorbed in a whole interval, and loss of CD34 + hematopoietic stem cells is avoided; determining the standardized dilution ratio of the phosphate buffer saline, and eliminating the influence of the lymphocyte separation medium with high buoyancy density on the sedimentation separation of the stem cells; the centrifugal rate after the phosphate buffer saline is diluted and the acceleration of speed increase and speed reduction in the centrifugal process are optimized, so that complete precipitation of CD34 + cells is ensured, and mechanical damage is reduced; and multiple measures are coordinated and matched, so that the separation efficiency of the CD34 + hematopoietic stem cells is improved, the purity is improved, and the separation cost is reduced.

Provided are methods for treating a subject of a solid tumor expressing GPC3 comprising administering to the subject an anti-GPC3 chimeric antigen receptor immunoresponsive cell wherein the administering is performed after or concurrently with subjecting the subject to a lymphopenia treatment. A kit for use in the method is also provided.

A method for treating peripheral T cell lymphoma. Specifically, the present invention relates to use of a compound represented by formula (I) or a pharmaceutically acceptable salt thereof in combination with the CHOP combination or CHOEP combination in the preparation of a drug for treating mature lymphocytic tumors.